about
RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects.Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV preventionShort communication: cheminformatics analysis to identify predictors of antiviral drug penetration into the female genital tractModels for predicting effective HIV chemoprevention in womenPharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.Pharmacologic opportunities for HIV prevention.HIV PrEP Trials: The Road to Success.The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue.Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infectionPharmacology of Antiretrovirals in the Female Genital Tract for HIV PreventionSeizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and OutcomesPharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitisCase Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infectionReview of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United StatesDepot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine inMinimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction ModelCerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal MeningitisReview: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
P50
Q30495060-4BEFC2B3-0DE8-49E4-A4FE-2D4539B00D84Q33769971-CF0E0F0D-5E30-443D-9086-B3252BEDF24EQ34399668-E109C8A8-783A-4A10-BEFB-81984A4BDA9DQ35102285-C8A12DA1-E84A-448E-8DC4-652F15B5FEA8Q36430073-E81EE387-F024-4A87-BE31-245911A89F04Q36905431-1EB35B71-8F86-45F5-ADEB-6895062AFE20Q37438644-0E5023D7-9E1B-4F4B-A588-859ABCBFFE47Q50123366-2D335443-E376-41AC-ADD1-BB8EF50B625CQ58442187-8634F758-2576-4C65-A98A-4E2355CA18DCQ60434051-78E783A5-E96A-4799-8941-9F825742421AQ89640613-91C2E841-72CC-4E42-AE5E-7A4D2B471161Q90477764-8530B6A8-B1C0-4746-A432-BDE07FE60DD7Q91244665-3963D8A6-8D93-4EB0-9E85-BE95752C1D84Q91994872-E23663C3-B9A3-4E1A-8C3B-2CB6CDD90E99Q92312792-07EAEAD4-1628-4F98-AC08-8F0D84E11CD5Q92669284-911C7271-20C4-4699-B6E4-29704C66253FQ92808094-9B82D1B0-723C-4B0F-9FC8-E05DEAF2E3EBQ94503691-9D1DEEB1-1D9C-4C36-AA79-25AC77697B8DQ96122302-0C561C86-27C0-4186-A506-75EF9248C308
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Melanie R Nicol
@ast
Melanie R Nicol
@en
Melanie R Nicol
@es
Melanie R Nicol
@nl
type
label
Melanie R Nicol
@ast
Melanie R Nicol
@en
Melanie R Nicol
@es
Melanie R Nicol
@nl
prefLabel
Melanie R Nicol
@ast
Melanie R Nicol
@en
Melanie R Nicol
@es
Melanie R Nicol
@nl
P106
P1153
36632552300
P21
P31
P496
0000-0001-5513-5509